PT  - JOURNAL ARTICLE
AU  - Lorenzo-Redondo, Ramon
AU  - Nam, Hannah H.
AU  - Roberts, Scott C.
AU  - Simons, Lacy M.
AU  - Jennings, Lawrence J.
AU  - Qi, Chao
AU  - Achenbach, Chad J.
AU  - Hauser, Alan R.
AU  - Ison, Michael G.
AU  - Hultquist, Judd F.
AU  - Ozer, Egon A.
TI  - A Unique Clade of SARS-CoV-2 Viruses is Associated with Lower Viral Loads in Patient Upper Airways
AID  - 10.1101/2020.05.19.20107144
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.19.20107144
4099  - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20107144.short
4100  - http://medrxiv.org/content/early/2020/05/26/2020.05.19.20107144.full
AB  - The rapid spread of SARS-CoV-2, the causative agent of Coronavirus disease 2019 (COVID-19), has been accompanied by the emergence of distinct viral clades, though their clinical significance remains unclear. Here, we examined the genome sequences of 88 SARS-CoV-2 viruses from COVID-19 patients in Chicago, USA and identified three distinct phylogenetic clades. Clade 1 was most closely related to clades centered in New York, and showed evidence of rapid expansion across the USA, while Clade 3 was most closely related to those in Washington. Clade 2 was localized primarily to the Chicago area with limited evidence of expansion elsewhere. Average viral loads in the airways of patients infected with the rapidly spreading Clade 1 viruses were significantly higher than those of the poorly spreading Clade 2. These results show that multiple variants of SARS-CoV-2 are circulating in the USA that differ in their relative airway viral loads and potential for expansion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by: a Dixon Translational Research Grant made possible by the generous support of the Dixon family (E.A.O. and J.F.H.); a COVID-19 Supplemental Research award from the Northwestern Center for Advanced Technologies (NUCATS - M.G.I., C.J.A., and J.F.H.), the Gilead Sciences Research Scholars Program in HIV (J.F.H.), and NIH grants K22 AI136691 (J.F.H.), U19 AI135964 (E.A.O., A.R.H.), K24 AI04831 (A.R.H.), and T32 AI095207 (H.H.N., S.C.R.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequence data that support the findings of this study have been deposited in GISAID (https://www.gisaid.org/) with the accession codes given in Supplemental Table 1